Inhibrx Stock Today

INBX Stock  USD 15.64  0.06  0.39%   

Performance

5 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Over 83

 
High
 
Low
Very High
Inhibrx is trading at 15.64 as of the 12th of October 2024; that is 0.39 percent increase since the beginning of the trading day. The stock's open price was 15.58. Inhibrx has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Inhibrx symbol was changed from INXB,INXBV on 31st of May 2024. Equity ratings for Inhibrx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2022 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of August 2020
Category
Healthcare
Classification
Health Care
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.48 M outstanding shares of which 742.52 K shares are currently shorted by private and institutional investors with about 5.76 trading days to cover. More on Inhibrx

Moving together with Inhibrx Stock

  0.73DMAC DiaMedica TherapeuticsPairCorr

Moving against Inhibrx Stock

  0.61VALN Valneva SE ADRPairCorr
  0.53DRMA Dermata TherapeuticsPairCorr
  0.35CDIOW Cardio DiagnosticsPairCorr
  0.32ME 23Andme HoldingPairCorr

Inhibrx Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Older SymbolINXB
Thematic IdeaBiotech (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00560.0058
Notably Down
Slightly volatile
Total Current Liabilities59.1 M56.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total111.2 M208.1 M
Way Down
Slightly volatile
Total Assets323.3 M307.9 M
Sufficiently Up
Slightly volatile
Total Current Assets310.1 M295.4 M
Sufficiently Up
Slightly volatile
Debt Levels
Inhibrx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inhibrx's financial leverage. It provides some insight into what part of Inhibrx's total assets is financed by creditors.
Liquidity
Inhibrx currently holds 210.14 M in liabilities with Debt to Equity (D/E) ratio of 4.22, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Inhibrx has a current ratio of 7.36, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Inhibrx's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

4.82 Million
Inhibrx (INBX) is traded on NASDAQ Exchange in USA. It is located in 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 and employs 166 people. Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. Inhibrx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 225.53 M. Inhibrx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.48 M outstanding shares of which 742.52 K shares are currently shorted by private and institutional investors with about 5.76 trading days to cover. Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52.
Check Inhibrx Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Inhibrx is $225.53 Million. Over half of Inhibrx's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Inhibrx Ownership Details

Inhibrx Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-03-31
704.8 K
Tang Capital Management Llc2024-03-31
700 K
Qube Research & Technologies2024-03-31
543 K
Mmcap International Inc. Spc2024-03-31
451.4 K
Ubs Group Ag2024-03-31
445.2 K
Slotnik Capital Llc2024-03-31
419.8 K
Test Hedge Fund Mgmt2024-03-31
334 K
Citigroup Inc2024-03-31
331.3 K
Northern Trust Corp2024-03-31
307.5 K
Viking Global Investors Lp2024-03-31
7.2 M
Perceptive Advisors Llc2024-03-31
4.3 M
View Inhibrx Diagnostics

Inhibrx Historical Income Statement

At this time, Inhibrx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 30.9 M in 2024, despite the fact that Net Loss is likely to grow to (124.2 M). View More Fundamentals

Inhibrx Stock Against Markets

Inhibrx Corporate Management

Leah JDCorporate VPProfile
Mark LappeChairman, FounderProfile
Charbel PharmDVice PlanningProfile
BS CPAChief OfficerProfile
Jeffrey JensenExecutive OfficerProfile
Brendan EckelmanExecutive OfficerProfile
Carlos BaisExecutive SciencesProfile

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.